VaxInnate, a privately-held biotechnology company is pioneering breakthrough technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, a potent stimulator of the innate immune system. Using this technology, vaccines can be produced by low-cost, highly scalable recombinant DNA techniques, avoiding many of the challenges and pitfalls of egg-based or cell-culture vaccine production. This vaccine platform is based on Toll-like Receptor (TLR) technology, which dramatically improves vaccine immunogenicity and efficacy. VaxInnate’s vaccines focus on infectious diseases, including seasonal and pandemic flu, dengue and respiratory syncytial virus (RSV).
Our rapid response manufacturing capabilities in response to pandemic onset are unmatched. We can generate at least 300 million doses within 5-6 months, with first doses becoming available as soon as 12 weeks. In the event of a rapidly emerging pandemic, such speed is a distinct advantage.
Our employees are a significant part of our success. From bench scientists to our management team, each employee takes pride in contributing to the company’s mission and works efficiently to help VaxInnate meet its goals.